Star Therapeutics Raises $200 Million to Push Preclinical Drugs Into Clinic

Star Therapeutics has raised $200 million in private financing to move its preclinical pipeline into human studies, co-led by OrbiMed and Janus Henderson Investors. The South San Francisco biotech plans to use the capital to advance current preclinical assets into clinical development and add new programs to its roster.

The syndicate runs deep. Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments, Soleus Capital, and a sovereign wealth fund all joined the round. Janus Henderson's Vish Sridharan joins Star's board as an observer in connection with the deal.

The raise lands on the heels of a landmark exit. In July 2026, Incyte acquired Star's wholly owned subsidiary Vega Therapeutics in a transaction valued at up to $2 billion. That deal included latarcibart, also known as VGA039, a novel monoclonal antibody now in Phase 3 development for von Willebrand disease — a bleeding disorder where patients have limited options.

What does this change for Star?

The company gets fresh ammunition to repeat its playbook: build what it calls potential best-in-disease therapies, spin out or sell them, and start again. Star's team has developed four first-in-class therapies that are either in Phase 3 development or have reached commercialization. Team members have also contributed to four acquisitions involving Vega Therapeutics, DICE Therapeutics, True North Therapeutics, and iPierian.

The spinout machine keeps running, too. In September 2026, Star spinout Electra Therapeutics began trading on Nasdaq under the ticker ETRA. Two major liquidity events within three months — the Incyte buyout and the Electra listing — explain why a preclinical-stage company attracted a $200 million round with this caliber of investor.

CEO Adam Rosenthal, Ph.D., frames the financing as a turning point. "Our mission is to develop best-in-disease therapies at scale for the millions of patients with diseases of significant unmet need," Rosenthal said. "This financing marks the next phase for Star, building on our team's track record of discovering and developing novel medicines. With an experienced team, a growing pipeline and the support of a top-tier investor base, we are well positioned to advance our current programs into the clinic and continue to add new, highly innovative programs to our pipeline in order to meaningfully improve patient outcomes."

OrbiMed's conviction rests on history. Carl L. Gordon, Ph.D., CFA, Managing Partner at OrbiMed, said: "I have worked with this team across three different companies, and have seen firsthand their ability to identify important therapeutic opportunities and translate them into medicines with the potential to make an impact for patients. We believe Star has the team, scientific approach and pipeline to build on those achievements in its next phase of growth."

Janus Henderson, for its part, rarely writes checks at this stage — and says so explicitly. "Star stood out to us because of the strength of its team and its proven ability to invent and develop innovative therapies. We do not often invest in companies at this stage of development, which reflects our conviction in Star's ability to repeatedly identify areas of significant unmet need and develop differentiated therapies to address them," said Vish Sridharan, M.D., Assistant Portfolio Manager and Research Analyst at Janus Henderson Investors. "We look forward to supporting the team as it advances its growing pipeline into the clinic and continues to develop the next generation of therapies for patients."

What to watch next

Star's stated plan is straightforward: push existing preclinical programs toward human studies while hunting for additional therapeutic candidates. The company says its approach pairs scientific discovery with drug development expertise and a repeated knack for finding diseases where patients run out of treatment options.

For practitioners tracking the biotech funding cycle, the signal is clear: a team with four exits behind it can still raise nine figures pre-clinically — provided the exits were worth $2 billion. If Star converts this round into clinical entries on schedule, expect its next spinout or sale conversation to start from a higher base.